|
|
Lu X, Xie S, Mou D, Peng M. Relationship between MRI imaging characteristics and serum markers CEA, CA199, CA125 levels in ovarian cancer patients. Int J Radiat Res 2025; 23 (3) :513-519 URL: http://ijrr.com/article-1-6521-en.html
Department of Gynecology, The First People's Hospital of Zunyi, Zunyi, China , xsy419848977@163.com
Abstract: (826 Views)
Background: To investigate the correlation between magnetic resonance imaging (MRI) imaging characteristics and serum markers carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and carbohydrate antigen 125 (CA125) levels in ovarian cancer patients. Materials and Methods: A retrospective analysis of 85 patients with ovarian cancer diagnosed by postoperative pathological results in our hospital was carried out. MRI imaging data and hematological indexes of patients were collected to analyze the relationship between imaging characteristics of ovarian cancer patients and serum CEA, CA199, CA125 levels. Results: The main morphology of ovarian cancer was irregular, with solid lesions and visible septal changes and wall nodules. After enhancement, the septal or parietal nodules also significantly enhanced, accompanied by abdominal effusion, peritoneal metastasis, and lymph node metastasis. Serum CEA (66.33±6.54) g/ml, CA199 (185.03±20.71) U/ml, CA125 (224.62±23.82) U/ml. The results of univariate analysis showed that patients with ovarian cancer wall nodules, peritoneal metastasis, and lymph node metastasis had statistically significant differences in serum CEA, CA199, and CA125 concentrations (P<0.05). Pearson's results showed that wall nodules, peritoneal metastasis, and lymph node metastasis were positively correlated with serum CEA, CA199, and CA125 levels, respectively (P<0.05). Conclusion: Ovarian cancer MRI has certain characteristics related to CEA, CA199, CA125 concentrations, which can be used to diagnose the prognosis of ovarian cancer.
References
1. 1. Sadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, et al. (2022) O-RADS MRI risk stratification system: Guide for assessing Adnexal lesions from the ACR O-RADS committee. Radiology, 303(1): 35-47. [ DOI:10.1148/radiol.204371] 2. Tang T, Lai H, Huang X, Gu L, Shi H (2021) Application of serum markers in diagnosis and staging of ovarian endometriosis. J Obstet Gynaecol Res, 47(4): 1441-50. [ DOI:10.1111/jog.14654] 3. Cheng X and Fang Q (2022) Thigh muscle MRI Edema Features of dermatomyositis patients with ovarian cancer: A report of three cases. Cureus, 14(4): e24337. [ DOI:10.7759/cureus.24337] 4. Fang M, Huang S, Dong J, Yan H, Fang X, Zhang P, et al. (2022) A preliminary exploration using imaging methods to predict the possibility of the recurrence of serous ovarian cancer in Patients undergoing total resection. Front Oncol, 12: 754067. [ DOI:10.3389/fonc.2022.754067] 5. Fu M, Solovey K, Salzman O, Alterovitz R (2023) Toward certifiable optimal motion planning for medical steerable needles. Int J Rob Res, 42(10): 798-826. [ DOI:10.1177/02783649231165818] 6. Kelleher M, Singh R, O'Driscoll CM, Melgar S (2019) Carcinoembryonic antigen (CEACAM) family members and inflammatory bowel disease. Cytokine Growth Factor Rev, 47: 21-31. [ DOI:10.1016/j.cytogfr.2019.05.008] 7. Götz L, Rueckschloss U, Balk G, Pfeiffer V, Ergün S, Kleefeldt F (2023) The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer. Front Immunol, 14: 1295232. [ DOI:10.3389/fimmu.2023.1295232] 8. Li L, Guo C, Wan JL, Fan QS, Xu XL, Fu YF (2022) The use of carcinoembryonic antigen levels to predict lung nodule malignancy: a meta-analysis. Acta Clin Belg, 77(1): 227-32. [ DOI:10.1080/17843286.2020.1797330] 9. Liu Y, Du Z, Ji J, Li J, Bi D, Tang F (2020) Bidirectional association between serum carcinoembryonic antigen and metabolic syndrome among the Chinese male population: two cohort studies. Lipids Health Dis, 19(1): 233. [ DOI:10.1186/s12944-020-01411-7] 10. Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, et al. (2019) A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol, 35(6): 294-305. [ DOI:10.3393/ac.2019.11.13] 11. Shibata C, Nakano T, Yasumoto A, Mitamura A, Sawada K, Ogawa H, et al. (2022) Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer. BMC Surg, 22(1): 213. [ DOI:10.1186/s12893-022-01667-z] 12. Silveira MJ, Martins C, Cruz T, Castro F, Amorim-Costa Â, Chester K, et al. (2023) scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells. J Nanobiotechnology, 21(1): 357. [ DOI:10.1186/s12951-023-02126-4] 13. Pian G, Shin JS, Yoon S, Oh SY (2021) Prognostic reappraisal of postoperative carcinoembryonic antigen in T1-2N0 colorectal cancer. Anticancer Res, 41(2): 1101-10. [ DOI:10.21873/anticanres.14868] 14. Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, et al. (2021) Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer, 1875(2): 188409. [ DOI:10.1016/j.bbcan.2020.188409] 15. Qing X, Liu L, Mao X (2022) A clinical diagnostic value analysis of serum CA125, CA199, and HE4 in women with early ovarian cancer: Systematic review and meta-analysis. Comput Math Methods Med, 2022: 9339325. [ DOI:10.1155/2022/9339325] 16. Lu Y, Yu H, Qin S, Chen M, Chen H, Hu Z, et al. (2020) Single and combined use of preoperative inflammatory biomarkers and CA199 in Diagnosing pancreatic cancer. Clin Lab, 66(11): 2197-2204. [ DOI:10.7754/Clin.Lab.2020.200111] 17. Jiang Q, Qian H, Mei L, Sun Q, Cheng X, Huang W, et al. (2022) Effect of bevacizumab plus paclitaxel and carboplatin regimen on prognostic survival of ovarian cancer patients. Am J Transl Res, 14(12): 8761-7. 18. Jiao X, Peng T, Liang Z, Hu Y, Meng B, Zhao Y, et al. (2022) Lateral flow immunoassay based on time-resolved fluorescence microspheres for rapid and quantitative screening CA199 in human serum. Int J Mol Sci, 23(17): 9991. [ DOI:10.3390/ijms23179991] 19. Huang D, Lin Q, Song J, Xu B (2021) Prognostic value of pretreatment serum CA199 in patients with locally advanced rectal cancer treated with CRT followed by TME with normal pretreatment carcinoembryonic antigen levels. Dig Surg, 38(1): 24-9. [ DOI:10.1159/000508442] 20. Shuang T, Wang Y, Zhao L, Zhang K, Yin P, Guo L, et al. (2022) Extremely high serum CA19-9 level along with elevated D-dimer in assisting detection of ruptured ovarian endometriosis. Ann Med, 54(1): 1444-51. [ DOI:10.1080/07853890.2022.2074534] 21. Guo B, Lian W, Liu S, Cao Y, Liu J (2019) Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer. Oncol Lett, 17(6): 5523-8. [ DOI:10.3892/ol.2019.10264] 22. Chen J, Fan L, Yang Z, Yang D (2024) Comparison of results and age-related changes in establishing reference intervals for CEA, AFP, CA125, and CA199 using four indirect methods. Pract Lab Med, 38: e00353. [ DOI:10.1016/j.plabm.2023.e00353] 23. Zhou D, Fan X, Xie S, Lu M, Gao L, Zhang R, et al. (2024) Clinical application of serum CST4 combined with tumor markers in the diagnosis of digestive system malignant tumors. Oncol Lett, 28(2): 384. [ DOI:10.3892/ol.2024.14517] 24. Sachan A, Saluja SS, Nekarakanti PK, Nimisha, Mahajan B, Nag HH, et al. (2020) Raised CA19-9 and CEA have prognostic relevance in gallbladder carcinoma. BMC Cancer, 20(1): 826. [ DOI:10.1186/s12885-020-07334-x] 25. Mie T, Ozaka M, Okamoto T, Takeda T, Ushida Y, Mori C, et al. (2022) CA19-9 reduction after 4 months of treatment is a prognostic factor for locally advanced pancreatic cancer. In Vivo, 36(6): 2844-51. [ DOI:10.21873/invivo.13024] 26. Hou S, Jing J, Wang Y, Du L, Tian B, Xu X, et al. (2023) Evaluation of clinical diagnostic and prognostic value of preoperative serum carcinoembryonic antigen, CA19-9, and CA24-2 for colorectal cancer. Altern Ther Health Med, 29(6): 192-7. 27. Rosiek V, Wójcik-Giertuga M, Kos-Kudła B (2022) Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms. Cancer Treat Res Commun, 31: 100533. [ DOI:10.1016/j.ctarc.2022.100533] 28. Pedrazzoli P, Rosti G, Soresini E, Ciani S, Secondino S (2021) Serum tumor markers in germ cell tumours: From diagnosis to cure. Crit Rev Oncol Hematol, 159: 103224. [ DOI:10.1016/j.critrevonc.2021.103224] 29. Crombé A, Gauquelin L, Nougaret S, Chicart M, Pulido M, Floquet A, et al. (2021) Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy. Diagn Interv Imaging, 102(10): 629-39. [ DOI:10.1016/j.diii.2021.05.007] 30. Zhu C, Zhang N, Zhong A, Xiao K, Lu R, Guo L (2022) A combined strategy of TK1, HE4 and CA125 shows better diagnostic performance than risk of ovarian malignancy algorithm (ROMA) in ovarian carcinoma. Clin Chim Acta, 524: 43-50. [ DOI:10.1016/j.cca.2021.11.018] 31. Lee JH (2019) The feasibility of serum multiple tumor markers test between patients with primary pancreatic cancer and those with benign pancreatic cystic disease. Clin Lab, 65(10): 1859-1866. [ DOI:10.7754/Clin.Lab.2019.190222] 32. Touska P and Connor S (2021) New and Advanced magnetic resonance imaging diagnostic imaging techniques in the evaluation of cranial nerves and the skull base. Neuroimaging Clin N Am, 31(4): 665-84. [ DOI:10.1016/j.nic.2021.06.006] 33. Caredda G, Bassareo PP, Cau R, Mannelli L, Suri JS, Saba L (2022) Emerging role of cardiac magnetic resonance imaging in diagnosing myocarditis: A blunder or the way to get the problem sorted. J Thorac Imaging, 37(2): W12-12W27. [ DOI:10.1097/RTI.0000000000000634] 34. Jamilian M, Mansury S, Bahmani F, Heidar Z, Amirani E, Asemi Z (2018) The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. J Ovarian Res, 11(1): 80. [ DOI:10.1186/s13048-018-0457-1] 35. Desai S and Guddati AK (2023) Carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, prostate-specific antigen and other cancer markers: a primer on commonly used cancer markers. World J Oncol, 14(1): 4-14. [ DOI:10.14740/wjon1425] 36. Yoshida R (2021) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer, 28(6): 1167-80. [ DOI:10.1007/s12282-020-01148-2] 37. Bezerra R, Recchimuzzi DZ, Dos Santos Mota MM, Garcia M, de Menezes MR, Mazo PE, et al. (2019) Whole-body magnetic resonance imaging in the oncology setting: an overview and update on recent advances. J Comput Assist Tomogr, 43(1): 66-75. [ DOI:10.1097/RCT.0000000000000772] 38. Takami H, Graffeo CS, Perry A, Giannini C, Nakazato Y, Saito N, et al. (2023) Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathol, 40(2): 124-32. [ DOI:10.1007/s10014-023-00460-x] 39. Moro F, Bertoldo V, Avesani G, Moruzzi MC, Mascilini F, Bolomini G, et al. (2021) Fusion imaging in preoperative assessment of extent of disease in patients with advanced ovarian cancer: feasibility and agreement with laparoscopic findings. Ultrasound Obstet Gynecol, 58(6): 916-25. [ DOI:10.1002/uog.23650] 40. Sanna E, Tanca L, Cherchi C, Gramignano G, Oppi S, Chiai MG, et al. (2021) Decrease in Neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer. Diagnostics, 11(7): 1298. [ DOI:10.3390/diagnostics11071298] 41. Sussman D and Tannenbaum E (2023) Diffusion-weighted magnetic resonance imaging and morphological characteristics evaluation for outcome prediction of primary debulking surgery for advanced high-grade serous ovarian carcinoma. J Magn Reson Imaging, 57(5): 1350-1. [ DOI:10.1002/jmri.28447]
Send email to the article author
|
